MCID: PHC013
MIFTS: 41

Phaeochromocytoma malady

Categories: Cancer diseases

Aliases & Classifications for Phaeochromocytoma

Aliases & Descriptions for Phaeochromocytoma:

Name: Phaeochromocytoma 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0050771

Summaries for Phaeochromocytoma

MalaCards based summary : Phaeochromocytoma is related to pheochromocytoma and aneurysm. An important gene associated with Phaeochromocytoma is SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Neuroscience. The drugs Doxazosin and Phenoxybenzamine have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, testes and thyroid, and related phenotypes are Decreased viability and homeostasis/metabolism

Wikipedia : 71 A pheochromocytoma (from Greek phaios \"dark\", chroma \"color\", kytos \"cell\", -oma \"tumor\") or... more...

Related Diseases for Phaeochromocytoma

Diseases related to Phaeochromocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
id Related Disease Score Top Affiliating Genes
1 pheochromocytoma 29.3 CHGA NF1 NGF NPY POMC RET
2 aneurysm 29.1 CHGA NF1 RET SDHB SDHC VHL
3 protein s deficiency 29.0 POMC SST
4 cardiac arrest 28.7 RET SDHAF2 SDHB SDHC SDHD TMEM127
5 multiple endocrine neoplasia iia 10.8
6 multiple endocrine neoplasia iib 10.8
7 paraganglioma 10.4
8 main bronchus cancer 10.2 CHGA VHL
9 secondary syphilis 10.2 CHGA SST
10 brain edema 10.2 CHGA SST
11 trombiculiasis 10.2 CHGA NF1
12 paraganglioma and gastric stromal sarcoma 10.2 SDHB SDHC SDHD
13 glioma susceptibility 2 10.2 SDHB SDHC SDHD
14 amaurosis congenita, cone-rod type, with congenital hypertrichosis 10.2 SDHB SDHC SDHD
15 serous surface papilloma 10.2 SDHB SDHC SDHD
16 oculocutaneous albinism 10.2 CHGA SST
17 postgastrectomy syndrome 10.2 NF1 SST
18 gmppa-cdg 10.2 CHGA SST
19 glomangioma 10.1 SDHB SDHD
20 burning mouth syndrome type 3 10.1 POMC SST
21 renal hypoplasia, bilateral 10.1 POMC SST
22 water-clear cell adenoma 10.1 POMC SST
23 vaginal adenoma 10.1 POMC SST
24 brain ependymoma 10.1 NF1 SST
25 african histoplasmosis 10.1 POMC SST
26 volkmann contracture 10.1 CHGA SST
27 neutropenia, severe congenital, 5, autosomal recessive 10.1 CHGA RET SST
28 parietal lobe neoplasm 10.1 CHGA POMC
29 extragonadal nonseminomatous germ cell tumor 10.1 POMC SST
30 adult botryoid rhabdomyosarcoma 10.1 CHGA SST
31 muscular dystrophy-dystroglycanopathy , type a, 10 10.1 CHGA RET SST
32 cardioauditory syndrome of sanchez cascos 10.1 CHGA NPY SST
33 lung occult small cell carcinoma 10.1 NGF SST
34 central hypoventilation syndrome, congenital 10.1 NF1 RET SDHB SDHD
35 nonparalytic poliomyelitis 10.0 POMC SST
36 early-onset parkinson disease 10.0 POMC RET SST
37 multiple endocrine neoplasia 10.0
38 neurofibromatosis-noonan syndrome 10.0 NF1 SDHB SDHC SDHD
39 spinal stenosis 10.0 CHGA SST
40 breast secretory carcinoma 10.0 CHGA POMC SST
41 endocrine gland cancer 10.0 CHGA RET SDHD SST
42 eccrine papillary adenocarcinoma 10.0 CHGA POMC SST
43 anisometropia 10.0 CHGA POMC SST
44 neuroblastoma 10.0
45 mitochondrial dna depletion syndrome 5 10.0 CHGA POMC SST
46 endocrine organ benign neoplasm 10.0 NF1 POMC SST
47 childhood teratocarcinoma of the testis 10.0 CHGA RET SDHB SDHC SDHD
48 body dysmorphic disorder 10.0 NPY POMC SST
49 seborrheic dermatitis 9.9 NF1 RET SDHB SDHD VHL
50 malignant peritoneal solitary fibrous tumor 9.9 NGF NPY POMC

Graphical network of the top 20 diseases related to Phaeochromocytoma:



Diseases related to Phaeochromocytoma

Symptoms & Phenotypes for Phaeochromocytoma

GenomeRNAi Phenotypes related to Phaeochromocytoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.8 SDHD VHL NF1 RET
2 Decreased viability GR00221-A-2 9.8 RET SDHD VHL NF1
3 Decreased viability GR00221-A-4 9.8 RET SDHD NF1
4 Decreased viability GR00231-A 9.8 RET
5 Decreased viability GR00301-A 9.8 RET VHL
6 Decreased viability GR00381-A-1 9.8 SDHD
7 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 NF1 VHL

MGI Mouse Phenotypes related to Phaeochromocytoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 CHGA NF1 NGF NPY POMC RET
2 cardiovascular system MP:0005385 10.06 CHGA NF1 NGF POMC RET SDHB
3 growth/size/body region MP:0005378 10.06 VHL NGF NPY POMC RET SDHD
4 mortality/aging MP:0010768 10.02 POMC RET SDHB SDHC SDHD SST
5 endocrine/exocrine gland MP:0005379 9.98 CHGA NF1 POMC RET SDHB SDHD
6 neoplasm MP:0002006 9.73 NF1 POMC RET SDHB SDHD VHL
7 no phenotypic analysis MP:0003012 9.63 NGF POMC RET SDHB SST TMEM127
8 normal MP:0002873 9.56 SST VHL NF1 NGF NPY RET
9 renal/urinary system MP:0005367 9.1 CHGA NF1 NPY POMC RET VHL

Drugs & Therapeutics for Phaeochromocytoma

Drugs for Phaeochromocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxazosin Approved Phase 4 74191-85-8 3157
2
Phenoxybenzamine Approved Phase 4,Phase 2 59-96-1 4768
3 Adrenergic Agents Phase 4,Phase 2
4 Neurotransmitter Agents Phase 4,Phase 2
5 Adrenergic alpha-1 Receptor Antagonists Phase 4
6 Adrenergic alpha-Antagonists Phase 4,Phase 2
7 Adrenergic Antagonists Phase 4,Phase 2
8 Antihypertensive Agents Phase 4,Phase 2
9 Vasodilator Agents Phase 4,Phase 2
10
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
11
Ifosfamide Approved Phase 3 3778-73-2 3690
12
Lenograstim Approved Phase 3 135968-09-1
13
Mechlorethamine Approved Phase 3 51-75-2 4033
14
Somatostatin Approved Phase 2, Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
15
Doxil Approved June 1999 Phase 3,Phase 2 31703
16 3-Iodobenzylguanidine Phase 3,Phase 2,Phase 1
17 Radiopharmaceuticals Phase 3,Phase 2,Phase 1
18 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
19 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
20 Hormones Phase 2, Phase 3,Phase 1
21 Alkylating Agents Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
23 Isophosphamide mustard Phase 3
24 Topoisomerase Inhibitors Phase 3,Phase 2
25 Hormone Antagonists Phase 2, Phase 3,Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
27
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
28
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
29
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
30
Indinavir Approved Phase 2 150378-17-9 5362440
31
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
32
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
33
Carbidopa Approved Phase 2 28860-95-9 34359 38101
34
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
36
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
37
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
38
Tamoxifen Approved Phase 2 10540-29-1 2733526
39
Melphalan Approved Phase 2 148-82-3 4053 460612
40
Pancrelipase Approved Phase 2 53608-75-6
41
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
42
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
43
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
44
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
45
Lenvatinib Approved Phase 2 417716-92-8
46
nivolumab Approved Phase 2 946414-94-4
47
Pembrolizumab Approved Phase 2 1374853-91-4
48
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
49
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
50
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538

Interventional clinical trials:

(show top 50) (show all 81)
id Name Status NCT ID Phase
1 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
2 Phenoxybenzamine Versus Doxazosin in PCC Patients Recruiting NCT01379898 Phase 4
3 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3
4 Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
7 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3
8 Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3
9 RAD001 and Erlotinib in Patients With Neuroendocrine Tumors Unknown status NCT00843531 Phase 2
10 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
11 131MIBG to Treat Malignant Pheochromocytoma Completed NCT00028106 Phase 2
12 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Completed NCT00843037 Phase 2
13 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
14 RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid Completed NCT01152827 Phase 2
15 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2
16 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2
17 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2
18 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2
19 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2
20 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma Recruiting NCT01371201 Phase 2
21 Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Recruiting NCT03008369 Phase 2
22 Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2
23 Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Recruiting NCT00107289 Phase 2
24 MIBG Therapy for Patients With MIBG Avid Tumors Recruiting NCT02378428 Phase 2
25 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Recruiting NCT02936323 Phase 1, Phase 2
26 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
27 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
28 A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
29 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting NCT01967576 Phase 2
30 Dovitinib in Neuroendocrine Tumors Active, not recruiting NCT01635907 Phase 2
31 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Active, not recruiting NCT01237457 Phase 2
32 A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer Not yet recruiting NCT03165721 Phase 2
33 Phase 2 Study of ONC201 in Neuroendocrine Tumors Not yet recruiting NCT03034200 Phase 2
34 Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Terminated NCT01340794 Phase 2
35 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2
36 Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery Withdrawn NCT00770705 Phase 2
37 ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Completed NCT00339131 Phase 1
38 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
39 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1
40 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1
41 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1
42 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Not yet recruiting NCT02831179 Phase 1
43 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
44 Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Withdrawn NCT01941849 Phase 1
45 Evaluation of Plasma Catecholamine Concentration During Surgery Unknown status NCT00948181
46 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335
47 Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma Approved for marketing NCT00730444
48 Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma Completed NCT01022515
49 Diagnosis and Treatment of Pheochromocytoma Completed NCT00001229
50 I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma Completed NCT00590096

Search NIH Clinical Center for Phaeochromocytoma

Genetic Tests for Phaeochromocytoma

Anatomical Context for Phaeochromocytoma

MalaCards organs/tissues related to Phaeochromocytoma:

39
Adrenal Gland, Testes, Thyroid, Heart, Pituitary, Breast, Adrenal Cortex

Publications for Phaeochromocytoma

Articles related to Phaeochromocytoma:

(show top 50) (show all 605)
id Title Authors Year
1
Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline SDHx Gene Mutation. ( 28179334 )
2017
2
Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma. ( 27856506 )
2017
3
Is there an optimal preoperative management strategy for phaeochromocytoma/paraganglioma? ( 27696513 )
2017
4
Phaeochromocytoma and Paraganglioma. ( 27888488 )
2016
5
Recurrence of phaeochromocytoma in pregnancy in a patient with multiple endocrine neoplasia 2A: a case report and review of literature. ( 27808580 )
2016
6
Inappropriate adrenoreceptor blockade prior to phaeochromocytoma removal is perhaps a 'timely reappraisal'? ( 27332792 )
2016
7
Phaeochromocytoma presenting as an acute coronary syndrome. ( 27797837 )
2016
8
Successful management of phaeochromocytoma in the third trimester of pregnancy with the use of rapid sequential alpha-adrenergic blockage. ( 26792534 )
2016
9
Disease-modifying polymorphisms and C609Y mutation of RET associated with high penetrance of phaeochromocytoma and low rate of MTC in MEN2A. ( 27994876 )
2016
10
Diagnosis and Management of Hereditary Phaeochromocytoma and Paraganglioma. ( 27075351 )
2016
11
Rapid-sequence MRI for long-term surveillance for paraganglioma and phaeochromocytoma in patients with succinate dehydrogenase (SDHx) mutations. ( 27634942 )
2016
12
Endoprosthetic reconstruction for metastatic phaeochromocytoma in the distal femur: A case report. ( 28018063 )
2016
13
Doxazosin treatment of phaeochromocytoma during pregnancy: placental transfer and disposition in breast milk. ( 27194370 )
2016
14
ANNALS EXPRESS: Single-centre study of the diagnostic performance of plasma metanephrines with seated sampling for the diagnosis of phaeochromocytoma/paraganglioma. ( 27170024 )
2016
15
Phaeochromocytoma presenting with ST segment elevation myocardial infarction. ( 26857585 )
2016
16
Phaeochromocytoma presenting with labile blood pressures following coronary artery bypass grafting. ( 27699857 )
2016
17
Phaeochromocytoma and transient left ventricular apical ballooning syndrome. ( 27505337 )
2016
18
Primary hypercortisolism and phaeochromocytoma next to, but not related to, each other. ( 27073149 )
2016
19
Unusual presentation of phaeochromocytoma. ( 27166010 )
2016
20
Invasive phaeochromocytoma presenting as a right atrial mass. ( 26632094 )
2016
21
Occurrence of phaeochromocytoma tumours in RET mutation carriers - a single-centre study. ( 26884116 )
2016
22
Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. ( 26998836 )
2016
23
Screening for phaeochromocytoma and paraganglioma: impact of using supine reference intervals for plasma metanephrines with samples collected from fasted/seated patients. ( 27166307 )
2016
24
Malignant phaeochromocytoma with cavoatrial extension imaged with (123)I-MIBG. ( 26932713 )
2016
25
Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. ( 26839173 )
2016
26
Preoperative alpha-blockade in phaeochromocytoma and paraganglioma: is it always necessary? ( 27864838 )
2016
27
European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. ( 27048283 )
2016
28
Cardiogenic shock induced by a voluminous phaeochromocytoma rescued by concomitant extracorporeal life support and open left adrenalectomy. ( 27068551 )
2016
29
Phaeochromocytoma and acth-dependent cushing's syndrome: Tumor crf-secretion can mimic pituitary cushing's disease. ( 26433209 )
2015
30
Adrenal insufficiency in a child following unilateral excision of a dual-hormone secreting phaeochromocytoma. ( 26113981 )
2015
31
Recurrent phaeochromocytoma along the laparoscopic portal sites. ( 25735583 )
2015
32
Perioperative management of combined surgery for phaeochromocytoma and double outlet right ventricle: A rare combination. ( 26195836 )
2015
33
Dexmedetomidine for anaesthetic management of phaeochromocytoma in a child with von Hippel-Lindau type 2 syndrome. ( 26019360 )
2015
34
Laparoscopic adrenalectomy for phaeochromocytoma: a case series. ( 26645753 )
2015
35
Diagnosing phaeochromocytoma/paraganglioma in a patient presenting with critical illness: biochemistry versus imaging. ( 25683095 )
2015
36
Phaeochromocytoma with hypercortisolism and hypercalcaemia. ( 26446319 )
2015
37
Laparoscopic adrenalectomy for phaeochromocytoma: a case series. ( 26922446 )
2015
38
Phaeochromocytoma presenting with pseudo-intestinal obstruction and lactic acidosis. ( 26311913 )
2015
39
A review of the management of positive biochemical screening for phaeochromocytoma and paraganglioma: aA salutary tale. ( 25651433 )
2015
40
Cushing's disease and co-existing phaeochromocytoma. ( 26184502 )
2015
41
Anaesthetic management of a case of adrenal and extra-adrenal phaeochromocytoma for preoperative embolisation. ( 25838596 )
2015
42
Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis. ( 25883647 )
2015
43
Recurrence of Phaeochromocytoma and Abdominal Paraganglioma After Initial Surgical Intervention. ( 26170485 )
2015
44
Metastatic phaeochromocytoma in a 23-year-old woman with an unclassified variant in the von Hippel Lindau disease gene: how can the pathogenicity of this variant be determined? ( 25557216 )
2015
45
The genomic landscape of phaeochromocytoma. ( 25545346 )
2015
46
Neurofibromatosis-related phaeochromocytoma: two cases with large tumours and elevated plasma methoxytyramine. ( 26273474 )
2015
47
Perioperative anaesthetic management of phaeochromocytoma associated with uncorrected tetralogy of Fallot. ( 26903678 )
2015
48
Adrenaline rush: an unusual presentation of phaeochromocytoma. ( 26323979 )
2015
49
The effect of surgical treatment of phaeochromocytoma on concomitant arterial hypertension and diabetes mellitus in a single-centre retrospective study. ( 25667755 )
2014
50
Anaesthetic management of a dopamine-secreting phaeochromocytoma in multiple endocrine neoplasia 2B syndrome. ( 24963196 )
2014

Variations for Phaeochromocytoma

Expression for Phaeochromocytoma

Search GEO for disease gene expression data for Phaeochromocytoma.

Pathways for Phaeochromocytoma

GO Terms for Phaeochromocytoma

Cellular components related to Phaeochromocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 respiratory chain complex II GO:0045273 8.96 SDHB SDHC
2 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.8 SDHB SDHC SDHD

Biological processes related to Phaeochromocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.67 NF1 SST TMEM127 VHL
2 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.43 NF1 NGF
3 aerobic respiration GO:0009060 9.4 SDHB SDHC
4 regulation of blood pressure GO:0008217 9.33 CHGA NPY POMC
5 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 9.32 NF1 RET
6 regulation of appetite GO:0032098 9.26 NPY POMC
7 mitochondrial electron transport, succinate to ubiquinone GO:0006121 8.96 SDHAF2 SDHD
8 tricarboxylic acid cycle GO:0006099 8.92 SDHAF2 SDHB SDHC SDHD

Molecular functions related to Phaeochromocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.5 NPY POMC SST
2 electron carrier activity GO:0009055 9.43 SDHB SDHC SDHD
3 ubiquinone binding GO:0048039 9.16 SDHB SDHD
4 succinate dehydrogenase (ubiquinone) activity GO:0008177 8.96 SDHB SDHD
5 succinate dehydrogenase activity GO:0000104 8.62 SDHC SDHD

Sources for Phaeochromocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....